Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease

Wael El-Matary; Charles N Bernstein

doi:10.3389/fped.2020.00400

Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease

Front Pediatr. 2020 Jul 17:8:400. doi: 10.3389/fped.2020.00400. eCollection 2020.

Authors

Wael El-Matary^{1

2

3}, Charles N Bernstein^{3

4}

Affiliations

¹ Department of Pediatrics, University of Manitoba, Winnipeg, MB, Canada.
² Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.
³ IBD Clinical and Research Center, University of Manitoba, Winnipeg, MB, Canada.
⁴ Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.

Abstract

Inflammatory bowel disease (IBD) is a chronic, immune-mediated, non-curable disease. The incidence of IBD appears to have risen over the last few decades especially in the pediatric age group. IBD usually presents with gastrointestinal symptoms, including abdominal pain, diarrhea, and bleeding per rectum but can also be associated with systemic symptoms such as weight loss, fatigue, joint and skin problems, and psychological comorbidities. One major complication is gastrointestinal and extra-intestinal malignancy. This review discusses literature that focuses on cancer risk of pediatric-onset IBD.

Keywords: Crohn; IBD; cancer; colitis; inflammatory bowel disease; malignancy; pediatric.

Publication types

Review